UA117165C2 - Біциклічні гетероциклічні похідні як інгібітори бромодомену - Google Patents

Біциклічні гетероциклічні похідні як інгібітори бромодомену

Info

Publication number
UA117165C2
UA117165C2 UAA201608674A UAA201608674A UA117165C2 UA 117165 C2 UA117165 C2 UA 117165C2 UA A201608674 A UAA201608674 A UA A201608674A UA A201608674 A UAA201608674 A UA A201608674A UA 117165 C2 UA117165 C2 UA 117165C2
Authority
UA
Ukraine
Prior art keywords
bicyclic heterocyclic
heterocyclic derivatives
bromodomain inhibitors
pharmaceutically acceptable
diseases
Prior art date
Application number
UAA201608674A
Other languages
English (en)
Inventor
Сусанта Самадждар
Чандрасекхар Аббінені
Санджита Сасмал
Субраманіа Хосахаллі
Original Assignee
Оріон Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оріон Корпорейшн filed Critical Оріон Корпорейшн
Publication of UA117165C2 publication Critical patent/UA117165C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

У даному винаході запропоновані біциклічні гетероциклічні похідні формули (І), які можуть бути терапевтично корисні, особливо як інгібітори бромодомену: , (I) де R1, R2, R3, R4, L1, L2, Су1, Су2, X, n і пунктирна лінія мають значення, зазначені в описі, і їх фармацевтично прийнятні солі або фармацевтично прийнятні стереоізомери можна застосовувати для лікування або профілактики захворювань або порушень, зокрема їх можна використовувати для лікування захворювань або порушень, пов'язаних з інгібіторами бромодомену. У даному винаході також розкрите одержання зазначених сполук і фармацевтичних композицій, що включають щонайменше одне з біциклічних гетероциклічних похідних формули (І) разом з його фармацевтично прийнятним носієм, розріджувачем або ексципієнтом.
UAA201608674A 2014-01-09 2015-01-06 Біциклічні гетероциклічні похідні як інгібітори бромодомену UA117165C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN125CH2014 2014-01-09
PCT/IB2015/050090 WO2015104653A1 (en) 2014-01-09 2015-01-06 Bicyclic heterocyclic derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
UA117165C2 true UA117165C2 (uk) 2018-06-25

Family

ID=52462967

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201608674A UA117165C2 (uk) 2014-01-09 2015-01-06 Біциклічні гетероциклічні похідні як інгібітори бромодомену

Country Status (30)

Country Link
US (2) US10077259B2 (uk)
EP (1) EP3092227B1 (uk)
JP (1) JP6480944B2 (uk)
KR (1) KR102394518B1 (uk)
CN (1) CN106061966B (uk)
AU (1) AU2015205339B2 (uk)
BR (1) BR112016015311B1 (uk)
CA (1) CA2934788C (uk)
CL (1) CL2016001737A1 (uk)
CY (1) CY1122046T1 (uk)
DK (1) DK3092227T3 (uk)
EA (1) EA029224B1 (uk)
ES (1) ES2687497T3 (uk)
HR (1) HRP20181650T1 (uk)
HU (1) HUE041546T2 (uk)
IL (1) IL246140B (uk)
LT (1) LT3092227T (uk)
MA (1) MA39172B1 (uk)
MX (1) MX2016009052A (uk)
MY (1) MY190835A (uk)
PE (1) PE20161021A1 (uk)
PH (1) PH12016501355A1 (uk)
PL (1) PL3092227T3 (uk)
PT (1) PT3092227T (uk)
RS (1) RS57586B1 (uk)
SA (1) SA516371448B1 (uk)
SG (1) SG11201604916YA (uk)
SI (1) SI3092227T1 (uk)
UA (1) UA117165C2 (uk)
WO (1) WO2015104653A1 (uk)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022942B1 (pt) 2013-03-15 2022-02-22 Incyte Holdings Corporation Compostos heterocíciclos tricíclicos, método para inibir proteína bet in vitro e composição farmacêutica compreendendo os referidos compostos
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
NZ763740A (en) 2014-04-23 2023-06-30 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
US20180312496A1 (en) * 2015-07-02 2018-11-01 Orion Corporation Bicyclic heterocycle derivatives as bromodomain inhibitors
WO2017024408A1 (en) 2015-08-11 2017-02-16 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
WO2017024412A1 (en) 2015-08-12 2017-02-16 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN105198871A (zh) * 2015-11-06 2015-12-30 中国药科大学 一类喹喔啉酮类化合物及其制备方法和用途
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
JP2019513804A (ja) * 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ，インク． 治療用化合物
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
FI3472157T3 (fi) 2016-06-20 2023-06-01 Incyte Corp Bet-inhibiittorin kiteisiä kiinteitä muotoja
JP2020503312A (ja) 2016-12-22 2020-01-30 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換１，２，４−チアジアゾリルピロロンおよび１，２，４−チアジアゾリルヒダントイン、ならびにその塩、ならびにその除草剤としての使用
CN110392680A (zh) 2016-12-22 2019-10-29 拜耳作物科学股份公司 取代的唑基吡咯酮和唑基乙内酰脲及其盐及其作为除草活性物质的用途
WO2018161876A1 (zh) * 2017-03-08 2018-09-13 中国科学院上海药物研究所 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途
JP2020516672A (ja) 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ，インク． 治療用化合物
CN110092782B (zh) * 2018-01-30 2022-10-21 中国科学院广州生物医药与健康研究院 一种苯并六元氮杂环化合物及其制备方法和应用
CN110960528A (zh) * 2018-09-30 2020-04-07 四川大学 Ar和bet双重抑制剂及其用途
EP3873474A4 (en) 2018-10-30 2022-07-13 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS BET Inhibitors
WO2020208307A1 (en) 2019-04-11 2020-10-15 Orion Corporation Crystalline form of a bet-inhibitor and manufacture thereof
MX2022000050A (es) 2019-07-02 2022-05-24 Nuvation Bio Inc Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR102600176B1 (ko) * 2021-10-18 2023-11-10 주식회사 사피엔스바이오 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10259176A (ja) * 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
CN101068810B (zh) * 2004-09-28 2011-02-09 大塚制药株式会社 喹诺酮化合物
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
JP5191155B2 (ja) * 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
TW200918058A (en) * 2007-08-31 2009-05-01 Organon Nv TSH receptor antagonizing tetrahydroquinoline compounds
CA2699707C (en) * 2007-09-21 2016-05-17 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
WO2010074807A1 (en) * 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2012064744A2 (en) * 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) * 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
US9321750B2 (en) * 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
WO2013166015A1 (en) * 2012-04-30 2013-11-07 Anderson Gaweco Ror modulators and their uses
MX367420B (es) * 2013-03-14 2019-08-21 Convergene Llc Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
EP2978758B1 (en) * 2013-03-27 2017-02-08 Boehringer Ingelheim International GmbH Dihydroquinazolinone analogues as brd4 inhibitors

Also Published As

Publication number Publication date
CN106061966A (zh) 2016-10-26
US20160368906A1 (en) 2016-12-22
SI3092227T1 (sl) 2018-10-30
WO2015104653A1 (en) 2015-07-16
EP3092227B1 (en) 2018-07-11
IL246140A0 (en) 2016-08-02
AU2015205339A1 (en) 2016-07-07
CA2934788A1 (en) 2015-07-16
MA39172B1 (fr) 2018-10-31
PE20161021A1 (es) 2016-11-09
CN106061966B (zh) 2018-12-07
IL246140B (en) 2019-09-26
JP6480944B2 (ja) 2019-03-13
EP3092227A1 (en) 2016-11-16
PH12016501355B1 (en) 2017-02-06
US20180339982A1 (en) 2018-11-29
NZ721993A (en) 2021-05-28
EA029224B1 (ru) 2018-02-28
ES2687497T3 (es) 2018-10-25
JP2017502057A (ja) 2017-01-19
MY190835A (en) 2022-05-12
CA2934788C (en) 2021-12-07
PL3092227T3 (pl) 2018-12-31
DK3092227T3 (en) 2018-09-03
BR112016015311A2 (uk) 2017-08-08
BR112016015311B1 (pt) 2023-01-24
US10077259B2 (en) 2018-09-18
EA201691404A1 (ru) 2016-10-31
US10590118B2 (en) 2020-03-17
LT3092227T (lt) 2018-08-10
CL2016001737A1 (es) 2017-02-03
MA39172A1 (fr) 2018-04-30
SA516371448B1 (ar) 2018-10-15
HRP20181650T1 (hr) 2018-12-14
RS57586B1 (sr) 2018-11-30
AU2015205339B2 (en) 2018-07-05
PT3092227T (pt) 2018-10-24
HUE041546T2 (hu) 2019-05-28
SG11201604916YA (en) 2016-07-28
KR102394518B1 (ko) 2022-05-06
PH12016501355A1 (en) 2017-02-06
CY1122046T1 (el) 2020-07-31
KR20160106164A (ko) 2016-09-09
MX2016009052A (es) 2016-09-09

Similar Documents

Publication Publication Date Title
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12018501920B1 (en) Bromodomain inhibitors
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MY190429A (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2016007440A (es) Inhibidores del bromodominio.
TW201613864A (en) Novel compounds
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
TN2017000384A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
EA202091668A2 (ru) Ингибиторы калликреина плазмы человека